Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Timetable
開拓藥業
Kintor Pharmaceutical
COMPANY PROFILE

Kintor Pharmaceutical is a clinical-stage novel drug developer in China focused on the proprietary R&D of potential first-in-class and best-in-class drugs for cancers and other androgen receptor-related, or AR-related diseases.

Its lead drug candidate, Proxalutamide, is a potential best-in-class drug undergoing phase III clinical trials in China and phase II clinical trials in the United States for metastatic castration-resistant prostate cancer, or mCRPC as well as clinical trials for breast cancer.

The Group had developed a pipeline of five drug candidates as of 4 May 2020, for which it had obtained approvals to commence clinical trials in China, the United States and/or Taiwan. These clinical-stage drug candidates are composed of a phase III small molecule drug candidate, a phase II small molecule drug candidate, a phase II monoclonal antibody drug candidate, a phase I mTOR inhibitor drug candidate and an inhibitor of the hedgehog signal translation pathway.

In February 2018, the Group entered into a licence agreement with Pfizer, pursuant to which it obtained an exclusive global licence under certain patents and know-how to use, develop, manufacture and commercialise the monoclonal ALK-1 antibody designated by Pfizer as PF-03446962 and any pharmaceutical product in all dosage forms and formulations that includes or incorporates the Compound (ALK-1 Product) for the treatment of cancer.

The preparation for commercialisation in the near-term will be focused on the targeted launch of Proxalutamide in China for mCRPC. The Group acquired a parcel of land in Suzhou, on which it plans to build own manufacturing facilities for the manufacture. It is expected Suzhou facility will be ready for GMP manufacturing in the third quarter of 2020.

BASIC INFORMATION
MarketHong Kong (Main Board)
Business NatureHealth Care
Websitewww.kintor.com.cn
Board Lot500
Registrar & Transfer OfficeComputershare Hong Kong Investor Services
GLOBAL OFFERING
No. of Offer Shares92.35m shares
No. of International Offer Shares83.11m shares
No. of HK Offer Shares9.24m shares
Offer Price$17.80 - $20.15
Nominal ValueUS$ 0.0001 each
Stock Code9939
Sole SponsorHuatai Financial Holdings (Hong Kong)
Joint Global Coordinators, Joint Bookrunners and Joint Lead ManagersHuatai Financial Holdings (Hong Kong), UBS AG, China International Capital Corporation Hong Kong Securities
Joint Bookrunners and Joint Lead ManagersCMB International Capital, China Renaissance Securities (Hong Kong), Haitong International Securities, CCB International Capital, China Everbright Securities (HK)
Joint Lead ManagerSPDB International Capital
TIME TABLE
Application PeriodMay 12 (Tue) - Noon, May 15 (Fri)
Price Determination DateOn or Before 5pm, May 15 (Fri)
Result Announcement DateOn or Before May 21 (Thu)
Dispatch of Shares and Refund ChequesOn or Before May 21 (Thu)
Dealings in Shares commence onMay 22, 2020. (Fri)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
DIRECTORS
ExecutiveYouzhi Tong (Chairman)
Non-ExecutiveChuangxing Guo, Gang Lu, Jie Chen, Bing Chen, Xiaoyan Chen
Independent Non-ExecutiveMichael Min Xu, John Fenyu Jin, Wallace Wai Yim Yeung
MAJOR SHAREHOLDERS
董事童友之13.82%
董事郭創新13.82%
Legend Holdings7.31%
Stephen Hui Wang7.06%
Seq Medical5.22%
BioVenture Investment5.04%
INCOME STATEMENT (RMB'000)
(Year ended Dec 31)
20192018
Revenue0698--
Gross Profit09--
Pre-Taxed Profit(232,577)(108,484)--
Attributable Profit for the period(232,577)(108,484)--
OFFER STATISTICS (HK$)
Offer Price$17.80 - $20.15
Capitalization$6,575m - $7,443m
Unaudited pro forma adj NAV / share$4.79 - $5.36
USE OF PROCEEDS
Assuming the offer price being at the mid-point of $18.98, the net proceeds raised would be HK$1,642.7m, of which:
* $689.9m (42.0%) to the development and commercialisation of one of Core Products, Proxalutamide;
* $460.0m (28.0%) to the development and commercialisation of one of Core Products, Pyrilutamide;
* $230.0m (14.0%) to the ongoing and planned clinical trials for other clinical-stage drug candidates;
* $98.6m (6.0%) to the R&D of pre-clinical stage drug candidates;
* the balance of $164.3m (10.0%) as additional working capital.
CHART
IPO NEWS
No related information.
RELATED STOCK COMPARISON
Code Name Nominal Change %Change
01672ASCLETIS-Bup3.5000.2608.025%
01801INNOVENT BIOdown59.050-0.100-0.169%
01877JUNSHI BIO-Bup61.0002.0503.478%
02552HUA MEDICINE-Bup7.5200.1201.622%
02616CSTONE PHARMA-Bdown10.780-0.320-2.883%
02696HENLIUS-Bup63.0005.5009.565%
03681SINOMAB BIO-Bup3.9200.0601.554%
06160BEIGENEup121.6002.3001.928%
06185CANSINOBIO-Bup249.20023.80010.559%
06855ASCENTAGE-Bdown40.450-1.200-2.881%
09926AKESO-Bdown34.800-1.400-3.867%
09939KINTOR PHARMA-Bup19.2604.90034.123%
09966ALPHAMAB-Bup17.5000.6804.043%
09969INNOCARE-Bup14.6800.0400.273%
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
  Quote data is at least 15-min delayed,last updated: 13/07/2020 17:58
IPO Calculator
Name︰
--
--
--
Subscription --
Result Announcement --      Listing --
Offer Price︰--
Currency :
Listing Price
Board Lot :
Admission Fee*
:
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.003% and Stock Exchange trading fee of 0.005% (i.e. 1.008% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2020 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.